サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426222

モノクローナル抗体の世界市場レポート 2024

Monoclonal Antibodies (MAs) Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
モノクローナル抗体の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

モノクローナル抗体の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には12.8%の年間複合成長率（CAGR）で4,242億4,000万米ドルに成長すると予想されます。モノクローナル抗体（MAB）の予測期間における予想される成長は、治療用途の拡大、個別化医療アプローチの台頭、バイオシミラーとジェネリックの開発、併用療法の利用、パンデミックへの注目の高まりなど、いくつかの重要な要因と結びついています。準備の強化とバイオ医薬品への投資の増加。

コスト効率の高いバイオシミラーモノクローナル抗体の拡大は、モノクローナル抗体市場の拡大を推進する極めて重要な推進力となっています。バイオシミラーは、ヘルスケア費の高騰と薬剤費削減を求める政府の圧力に対抗するために設計されており、生物学的医薬品を低コストで複製し、バイオシミラーのモノクローナル抗体のコストは元の同等品より20%～25%低くなります。バイオシミラーの臨床試験プロセスの合理化は、コスト効率の向上に貢献します。インドの中央医薬品標準管理機構（CSDCO）による「類似生物製剤に関するガイドライン」は、インドのバイオシミラー医薬品業界に大きな前進をもたらします。

慢性疾患の有病率の拡大が、モノクローナル抗体市場を促進する触媒として浮上しています。治癒はしないが管理可能な慢性疾患では、特に調節不全の免疫応答や炎症の管理において、mAbによる治療が増加しています。衝撃的なことに、世界保健機関の2023年9月のデータは、年間4,100万人に達する世界の死亡者の74％が非感染性疾患（NCD）または慢性疾患によるものであることを明らかにしました。 NCD関連の早期死亡の86%が低・中所得国で発生しているというこれらの驚異的な数字は、慢性疾患への対処におけるmAbsの重要な役割を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のモノクローナル抗体市場、原料別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ネズミ
  • キメラ
  • ヒト化
  • ヒト
  • 世界のモノクローナル抗体市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗がん剤
  • 免疫学的
  • 抗感染性モノクローナル抗体
  • 神経薬理学
  • 心血管と脳血管
  • その他の用途
  • 世界のモノクローナル抗体市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 民間クリニック
  • 研究施設

第7章 地域および国の分析

  • 世界のモノクローナル抗体市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のモノクローナル抗体市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • モノクローナル抗体市場の競合情勢
  • モノクローナル抗体市場企業プロファイル
    • Johnson &Johnson
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Novartis International AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r13244

Monoclonal antibodies (MABs) are laboratory-created proteins designed to enhance the immune system's capabilities. These treatments are typically administered as IV solutions, often in specialized infusion centers. Antibodies function as vital components of the immune system by targeting and binding to antigens (foreign substances) to neutralize them.

There are several sources of monoclonal antibodies: murine, chimeric, humanized, and fully human. Murine antibodies contain two types of chains, one from a mouse and the other from a human. The prefix 'o-' in the International Nonproprietary Name (INN) identifies murine antibodies. They find applications in various fields such as anti-cancer treatments, immunology, anti-infective therapies, neuropharmacology, cardiovascular and cerebrovascular conditions. These antibodies are utilized across different sectors including hospitals, private clinics, and research institutes.

The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry. This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. Historical growth in the use of monoclonal antibodies (MABs) can be linked to several factors, including the rising prevalence of chronic diseases, increased investment in research and development (R&D), a growing awareness of the benefits of MABs, and the expanding elderly population's healthcare needs.

The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. Anticipated growth in the forecast period for monoclonal antibodies (MABs) is tied to several key factors, including the expansion of therapeutic applications, the rise of personalized medicine approaches, the development of biosimilars and generics, the utilization of combination therapies, increased focus on pandemic preparedness, and heightened investment in biopharmaceuticals.

The escalation of cost-efficient biosimilar monoclonal antibodies stands as a pivotal driver propelling the monoclonal antibody market's expansion. Biosimilars, designed to counter escalating healthcare costs and governmental pressures for reduced medication expenses, replicate biological drugs at a lower cost, with biosimilar monoclonal antibodies costing 20%-25% less than their original counterparts. The streamlined clinical trial processes for biosimilars contribute to their cost efficiency. India's 'Guidelines on Similar Biologics' by the Central Drugs Standard Control Organization (CSDCO) augur a significant uplift for the Indian biosimilar drug industry.

The escalating prevalence of chronic diseases emerges as a catalyst driving the monoclonal antibodies (mAbs) market. Chronic conditions, uncurable but manageable, have seen increased treatment with mAbs, particularly in managing dysregulated immune responses and inflammation. Shockingly, the World Health Organization's September 2023 data revealed that 74% of global deaths, amounting to 41 million annually, are due to noncommunicable diseases (NCDs) or chronic diseases. These staggering figures, with 86% of premature NCD-related deaths occurring in low- and middle-income countries, underscore the pivotal role of mAbs in addressing chronic ailments.

The market has witnessed numerous strategic initiatives, with top companies leveraging acquisitions, collaborations, and partnerships to expand product portfolios and global reach. In March 2022, Collaborations like Sanofi S.A.'s collaboration with Seagen Inc. to develop cancer-targeting antibody-drug conjugates (ADCs) and Boehringer Ingelheim's partnership with MabGenesis, Inc. for therapeutic monoclonal antibodies exemplify this trend. Additionally, innovative technologies like RenMice, pioneered by Biocytogen Pharmaceuticals, are revolutionizing antibody-based therapies by offering a range of fully human antibodies and T-cell receptor mice with proprietary intellectual property.

Major companies operating in the monoclonal antibodies market are introducing innovative technologies such as RenMice to gain a competitive edge in the market. RenMice offers strong assistance in the exploration of various antibody-based therapies, including fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For instance, in September 2023, Biocytogen Pharmaceuticals, a China-based international biotech company that drives the research and development of new drugs with innovative technologies launched RenMice series, encompassing a selection of independently created fully human antibody mice and TCR mice, all of which possess proprietary intellectual property.

The regulatory support from the U.S. Food and Drug Administration (FDA) has significantly contributed to market growth, especially in the rare disease treatment segment. Accelerated approvals granted to drugs like avelumab (BAVENCIO) for metastatic Merkel cell carcinoma (MCC) and TECENTRIQ (atezolizumab) for locally-advanced or metastatic urothelial carcinoma (MUC) underscore the FDA's pivotal role in advancing monoclonal antibody therapeutics, fostering market expansion, and addressing critical medical needs.

Major companies operating in the monoclonal antibodies (MABS) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Mylan N.V., Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc

North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Monoclonal Antibodies (MAs) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on monoclonal antibodies (mas) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for monoclonal antibodies (mas)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The monoclonal antibodies (mas) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Source: Murine; Chimeric; Humanized; Human
  • 2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAs); Neuropharmacological; Cardiovascular And Cerebrovascular; Other Applications
  • 3) By End Users: Hospitals; Private Clinics; Research Institute
  • Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Amgen Inc.; Novartis International AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Monoclonal Antibodies (MAs) Market Characteristics

3. Monoclonal Antibodies (MAs) Market Trends And Strategies

4. Monoclonal Antibodies (MAs) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Monoclonal Antibodies (MAs) Market Size and Growth

  • 5.1. Global Monoclonal Antibodies (MAs) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Monoclonal Antibodies (MAs) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Monoclonal Antibodies (MAs) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Monoclonal Antibodies (MAs) Market Segmentation

  • 6.1. Global Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Murine
  • Chimeric
  • Humanized
  • Human
  • 6.2. Global Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-Cancer
  • Immunological
  • Anti-Infective Monoclonal Antibodies (MAs)
  • Neuropharmacological
  • Cardiovascular And Cerebrovascular
  • Other Applications
  • 6.3. Global Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Private Clinics
  • Research Institute

7. Monoclonal Antibodies (MAs) Market Regional And Country Analysis

  • 7.1. Global Monoclonal Antibodies (MAs) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Monoclonal Antibodies (MAs) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Monoclonal Antibodies (MAs) Market

  • 8.1. Asia-Pacific Monoclonal Antibodies (MAs) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Monoclonal Antibodies (MAs) Market

  • 9.1. China Monoclonal Antibodies (MAs) Market Overview
  • 9.2. China Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Monoclonal Antibodies (MAs) Market

  • 10.1. India Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Monoclonal Antibodies (MAs) Market

  • 11.1. Japan Monoclonal Antibodies (MAs) Market Overview
  • 11.2. Japan Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Monoclonal Antibodies (MAs) Market

  • 12.1. Australia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Monoclonal Antibodies (MAs) Market

  • 13.1. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Monoclonal Antibodies (MAs) Market

  • 14.1. South Korea Monoclonal Antibodies (MAs) Market Overview
  • 14.2. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Monoclonal Antibodies (MAs) Market

  • 15.1. Western Europe Monoclonal Antibodies (MAs) Market Overview
  • 15.2. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Monoclonal Antibodies (MAs) Market

  • 16.1. UK Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Monoclonal Antibodies (MAs) Market

  • 17.1. Germany Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Monoclonal Antibodies (MAs) Market

  • 18.1. France Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Monoclonal Antibodies (MAs) Market

  • 19.1. Italy Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Monoclonal Antibodies (MAs) Market

  • 20.1. Spain Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Monoclonal Antibodies (MAs) Market

  • 21.1. Eastern Europe Monoclonal Antibodies (MAs) Market Overview
  • 21.2. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Monoclonal Antibodies (MAs) Market

  • 22.1. Russia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Monoclonal Antibodies (MAs) Market

  • 23.1. North America Monoclonal Antibodies (MAs) Market Overview
  • 23.2. North America Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Monoclonal Antibodies (MAs) Market

  • 24.1. USA Monoclonal Antibodies (MAs) Market Overview
  • 24.2. USA Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Monoclonal Antibodies (MAs) Market

  • 25.1. Canada Monoclonal Antibodies (MAs) Market Overview
  • 25.2. Canada Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Monoclonal Antibodies (MAs) Market

  • 26.1. South America Monoclonal Antibodies (MAs) Market Overview
  • 26.2. South America Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Monoclonal Antibodies (MAs) Market

  • 27.1. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Monoclonal Antibodies (MAs) Market

  • 28.1. Middle East Monoclonal Antibodies (MAs) Market Overview
  • 28.2. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Monoclonal Antibodies (MAs) Market

  • 29.1. Africa Monoclonal Antibodies (MAs) Market Overview
  • 29.2. Africa Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Monoclonal Antibodies (MAs) Market Competitive Landscape And Company Profiles

  • 30.1. Monoclonal Antibodies (MAs) Market Competitive Landscape
  • 30.2. Monoclonal Antibodies (MAs) Market Company Profiles
    • 30.2.1. Johnson & Johnson
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Amgen Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis International AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Monoclonal Antibodies (MAs) Market Competitive Benchmarking

32. Global Monoclonal Antibodies (MAs) Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAs) Market

34. Monoclonal Antibodies (MAs) Market Future Outlook and Potential Analysis

  • 34.1 Monoclonal Antibodies (MAs) Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Monoclonal Antibodies (MAs) Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Monoclonal Antibodies (MAs) Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer